Mike Ward
@biopharmamike.bsky.social
Life sciences & healthcare thought leader with 40+ years experience as journalist and analyst covering issues consequential to biopharma and Medtech stakeholders
Reposted by Mike Ward
Can someone point me in right direction to find stats relating to interactions of #bsky.social posts - impressions etc?
November 26, 2024 at 5:20 PM
Can someone point me in right direction to find stats relating to interactions of #bsky.social posts - impressions etc?
Latest in cell and gene therapy #CGT #Roche to acquire #Poseida Therapeutics innovative pipeline of non-viral, TSCM-rich CAR-T therapies & gene meds for up to $1.5bn. Poseida stockholders to get up to $13/share, comprised of $9/share cash plus non-tradeable CVR up to an aggregate of $4/share cash.
November 26, 2024 at 10:11 AM
Working on my annual #biopharma and #medtech “Winners & Losers” presentation for the Genesis 2024 conference. Happy to receive nominations for entry into the list - list them here or send to Michael.Ward@clarivate.com
November 25, 2024 at 10:11 AM
Working on my annual #biopharma and #medtech “Winners & Losers” presentation for the Genesis 2024 conference. Happy to receive nominations for entry into the list - list them here or send to Michael.Ward@clarivate.com
Just I thought I would let this network I have now joined and am interested in hearing and communicating about rational commentaries of life science events and newsflow #biotech #biopharma #medtech
November 24, 2024 at 6:03 PM
Just I thought I would let this network I have now joined and am interested in hearing and communicating about rational commentaries of life science events and newsflow #biotech #biopharma #medtech